Is EPRXF or XYLD a better dividend investment in 2026?

EPRXF currently yields 65.79% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: EPRXF offers higher current income.

What is the dividend yield difference between EPRXF and XYLD?

EPRXF has a forward dividend yield of 65.79% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 54.81 percentage points.

Home › Compare › EPRXF vs XYLD

EPRXF vs XYLD: Dividend Comparison 2026

EPRXF yields 65.79% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EPRXF wins by $836.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

EPRXF

● Live price

65.79%

Share price

$3.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$861.9K

Annual income

$216,014.89

Full EPRXF calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — EPRXF vs XYLD

📍 EPRXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EPRXF	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EPRXF + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EPRXF pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPRXF

Annual income on $10K today (after 15% tax)

$5,592.11/yr

After 10yr DRIP, annual income (after tax)

$183,612.66/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, EPRXF beats the other by $180,876.49/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPRXF + XYLD for your $10,000?

EPRXF: 50%XYLD: 50%

100% XYLD50/50100% EPRXF

Portfolio after 10yr

$443.6K

Annual income

$109,616.96/yr

Blended yield

24.71%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPRXF buys

XYLD buys

No recent congressional trades found for EPRXF or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEPRXFXYLD

Forward yield	65.79% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$861.9K ✓	$25.3K
Annual income after 10y	$216,014.89 ✓	$3,219.02
Total dividends collected	$726.7K ✓	$19.6K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: EPRXF vs XYLD ($10,000, DRIP)

Year	EPRXF Portfolio	EPRXF Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$17,279	$6,578.95	$10,818	$1,098.39	+$6.5K → EPRXF
2	$29,113	$10,624.05	$11,738	$1,222.51	+$17.4K → EPRXF
3	$47,879	$16,728.95	$12,774	$1,364.64	+$35.1K → EPRXF
4	$76,944	$25,713.03	$13,944	$1,527.86	+$63.0K → EPRXF
5	$120,949	$38,618.52	$15,270	$1,715.87	+$105.7K → EPRXF
6	$186,148	$56,733.31	$16,775	$1,933.09	+$169.4K → EPRXF
7	$280,783	$81,604.23	$18,490	$2,184.87	+$262.3K → EPRXF
8	$415,475	$115,037.79	$20,450	$2,477.63	+$395.0K → EPRXF
9	$603,645	$159,085.84	$22,697	$2,819.19	+$580.9K → EPRXF
10	$861,915	$216,014.89	$25,280	$3,219.02	+$836.6K → EPRXF

EPRXF vs XYLD: Complete Analysis 2026

EPRXF — Stock

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Full EPRXF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this EPRXF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPRXF vs SCHD EPRXF vs JEPI EPRXF vs O EPRXF vs KO EPRXF vs MAIN EPRXF vs QYLD EPRXF vs JEPQ EPRXF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.